A New Molecular Mechanism To Engineer Protean Agonism at a G Protein-Coupled Receptor.

نویسندگان

  • Anna De Min
  • Carlo Matera
  • Andreas Bock
  • Janine Holze
  • Jessica Kloeckner
  • Mathias Muth
  • Christian Traenkle
  • Marco De Amici
  • Terry Kenakin
  • Ulrike Holzgrabe
  • Clelia Dallanoce
  • Evi Kostenis
  • Klaus Mohr
  • Ramona Schrage
چکیده

Protean agonists are of great pharmacological interest as their behavior may change in magnitude and direction depending on the constitutive activity of a receptor. Yet, this intriguing phenomenon has been poorly described and understood, due to the lack of stable experimental systems and design strategies. In this study, we overcome both limitations: First, we demonstrate that modulation of the ionic strength in a defined experimental set-up allows for analysis of G protein-coupled receptor activation in the absence and presence of a specific amount of spontaneous receptor activity using the muscarinic M2 acetylcholine receptor as a model. Second, we employ this assay system to show that a dualsteric design principle, that is, molecular probes, carrying two pharmacophores to simultaneously adopt orthosteric and allosteric topography within a G protein-coupled receptor, may represent a novel approach to achieve protean agonism. We pinpoint three molecular requirements within dualsteric compounds that elicit protean agonism at the muscarinic M2 acetylcholine receptor. Using radioligand-binding and functional assays, we posit that dynamic ligand binding may be the mechanism underlying protean agonism of dualsteric ligands. Our findings provide both new mechanistic insights into the still enigmatic phenomenon of protean agonism and a rationale for the design of such compounds for a G protein-coupled receptor.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Missing links: mechanisms of protean agonism.

The concept of pharmacological efficacy has been much discussed recently with significant interest both in inverse agonists and in protean agonists (i.e., compounds with functional selectivity for different effector responses). Although first proposed in the mid-1990s, the pharmacological and therapeutic importance of these concepts is now receiving wider support. Two articles in recent issues ...

متن کامل

Both Ligand- and Cell-Specific Parameters Control Ligand Agonism in a Kinetic Model of G Protein–Coupled Receptor Signaling

G protein-coupled receptors (GPCRs) exist in multiple dynamic states (e.g., ligand-bound, inactive, G protein-coupled) that influence G protein activation and ultimately response generation. In quantitative models of GPCR signaling that incorporate these varied states, parameter values are often uncharacterized or varied over large ranges, making identification of important parameters and signa...

متن کامل

Considerations in the evaluation of inverse agonism and protean agonism at G protein-coupled receptors.

Over the past decade it has become accepted that G protein-coupled receptors (GPCRs) can activate G proteins and thus initiate signaling in the absence of agonist; this spontaneous receptor activity can be inhibited to varying degrees by antagonists, a phenomenon termed inverse ugonism. The modulation of spontaneous GPCR activity by the binding of specific ligands implies that receptors can int...

متن کامل

Protean agonism at histamine H3 receptors in vitro and in vivo.

G protein-coupled receptors (GPCRs) are allosteric proteins that adopt inactive (R) and active (R*) conformations in equilibrium. R* is promoted by agonists or occurs spontaneously, leading to constitutive activity of the receptor. Conversely, inverse agonists promote R and decrease constitutive activity. The existence of another pharmacological entity, referred to as "protean" agonists (after ...

متن کامل

Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR).

The concept of "biased agonism" arises from the recognition that the ability of an agonist to induce a receptor-mediated response (i.e. "efficacy") can differ across the multiple signal transduction pathways (e.g. G protein and β-arrestin (βarr)) emanating from a single GPCR. Despite the therapeutic promise of biased agonism, the molecular mechanism(s) whereby biased agonists selectively engage...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Molecular pharmacology

دوره 91 4  شماره 

صفحات  -

تاریخ انتشار 2017